|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although PTEN is the most frequently inactivated gene in prostate cancer, its mode of action is not fully understood.
|
19784964 |
2010 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity.
|
25436982 |
2015 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We review other phosphatases' roles as TSGs which regulate oncogenic PI3K signaling in PCa and discuss the functional similarity between cPAcP and PTEN in prostate carcinogenesis.
|
24747769 |
2014 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The potential prognostic role of the combined alterations in EGFR and PTEN in prostate cancer is not well established.
|
20208477 |
2010 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ERG, SLC45A3 and PTEN immunostaining and their association with pathological features and PSA progression-free survival were analyzed in 220 PrCa (PSMAR-Biobank, Barcelona, Spain).
|
29088771 |
2017 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PTEN loss is one of the most recurrent alterations in prostate cancer associated with an aggressive phenotype, however, the occurrence of PTEN loss in insignificant prostate cancer has not been reported and its role in the separation of insignificant from significant prostate cancer is unclear.
|
26612463 |
2016 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical (IHC) staining for PTEN was correlated with PD-L1 IHC using a series of resected human prostate cancer samples.
|
26260996 |
2015 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings demonstrate that loss of PTEN expression is an important factor in progression towards metastatic disease and could potentially serve as an early prognostic marker for prostate cancer metastasis.
|
17163422 |
2007 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TP53, PTEN, and RB1 tumor suppressor genes (TSGs) are recurrently altered in treatment-resistant prostate cancer.
|
30553611 |
2019 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Resveratrol downregulated the phosphatase and tensin homolog (PTEN)-targeting members of the oncogenic miR-17 family of miRNAs, which are overexpressed in prostate cancer.
|
28662290 |
2017 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We assessed 42 fresh frozen tissue samples of prostate cancer (PCA) obtained by radical prostatectomy, interrogating the TMPRSS2-ERG fusion gene along with PTEN gene status using Real Time PCR and FISH methods.
|
26424596 |
2016 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings suggest that MHY-449 induces apoptosis via downregulation of the Akt/FoxO1 and activation of ERK in androgen-independent, p53-null and PTEN-negative PC3 human prostate cancer cells.
|
24424889 |
2014 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed the combined value of TFF3 and PTEN in two cohorts: one is managed surgically for localized PCa and the second is managed non-surgically by androgen deprivation therapy for advanced disease.
|
31129769 |
2019 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data support the utility of PTEN IHC and <i>PTEN</i> FISH as complementary screening tools for PTEN loss in prostate cancer.
|
29029453 |
2017 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The oncogenomics of prostate cancer is reviewed with emphasis on androgen signaling, ETS gene family aberrations, and PTEN deletion.
|
21925305 |
2011 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings show how CBP and PTEN interact to mediate tumor suppression in the prostate, establishing a central role for histone modification in the etiology of prostate cancer and providing a rationale for clinical evaluation of epigenetic-targeted therapy in patients with prostate cancer.
|
24491799 |
2014 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Characterization of the prostate cancer transcriptome and genome has identified chromosomal rearrangements and copy number gains and losses, including ETS gene family fusions, PTEN loss and androgen receptor (AR) amplification, which drive prostate cancer development and progression to lethal, metastatic castration-resistant prostate cancer (CRPC).
|
22722839 |
2012 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
miR-21 can target and inhibit tumor suppressor gene PTEN expression to promote prostate cancer cell proliferation and invasion.
|
28107872 |
2017 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-106a contributes to prostate carcinoma progression through PTEN.
|
30655902 |
2019 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, the results achieved in the present study show that PTEN controls the cellular response to cetuximab in KRAS wild-type prostate carcinoma PC3 cells through the regulation of AKT phosphorylation and restoration of the functionality of EGFR downstream signaling.
|
19212633 |
2009 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.
|
20104229 |
2010 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
KLF5 inhibits angiogenesis in PTEN-deficient prostate cancer by attenuating AKT activation and subsequent HIF1α accumulation.
|
25896712 |
2015 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Conversely, an induction of cPLA2α expression led to an increase in pAKT levels in PTEN-mutated or deleted prostate cancer cells, while silencing of cPLA2α expression or pharmacological blocking cPLA2α action decreased pAKT levels.
|
26143945 |
2015 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, loss of PTEN may permit CXCR4 to progress prostate cancer to an advanced disease.
|
21076047 |
2011 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We focus on some key regulatory molecules, including the pro-apoptotic regulators p53, PTEN, caspases and Par-4, and the anti-apoptotic molecules Bcl-2, NF-kappaB and Akt, to discuss their roles in prostate cancer progression and their therapeutic implications in human prostate carcinoma.
|
15202013 |
2004 |